Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 211Triple Negative Breast Neoplasms 32Inflammatory Breast Neoplasms 21Breast Neoplasms, Male 5Primary Breast Cancer 3Neoplasms 3Carcinoma, Ductal, Breast 3Pathologic Complete Response 2HER2-negative Breast Cancer 2Cardiotoxicity 2Breast Diseases 2Women With Primary Breast Cancer 1Unilateral HER2 Positive Breast Cancer 1Sarcoma 1Resectable HER2-positive Breast Cancer 1Postoperative Complications 1Patient Acceptance of Health Care 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Ovarian Neoplasms 1Neutropenia 1Neoplastic Cells, Circulating 1Neoplasm Micrometastasis 1Neoadjuvant Operable Breast Cancer 1Kenny-Caffey syndrome, Type 1 1Hormone Receptor Positive HER-2 Negative Breast Cancer 1Her2-Positive Breast Cancer 1HR-positive,HER2-negative Breast Cancer 1HR+/HER2- Breast Cancer 1HER2-negative Early Breast Cancer 1HER2 Positive Early Breast Cancer 1

Interventions

pertuzumab 1Trastuzumab 1Paclitaxel 1Fluorouracil 1Epirubicin 1Cyclophosphamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Her2-Positive Breast Cancer × Epirubicin × Breast × Clear all
NCT01855828 2020-03-31

Phase 2 Trial of Pertuzumab and Trastuzumab With Weekly Paclitaxel and Chemotherapy for HER2 Positive Breast Cancer

Yale University

Phase 2 Completed
50 enrolled 13 charts
Breast

Her2-Positive Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡